相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
H. Kadara et al.
ANNALS OF ONCOLOGY (2017)
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus
Toshiyasu Ojima et al.
SURGERY TODAY (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma
Taro Ohba et al.
SURGERY TODAY (2016)
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria
Hiroshi Katayama et al.
SURGERY TODAY (2016)
Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure
Takahisa Kawamura et al.
CANCER SCIENCE (2016)
Gene aberrations for precision medicine against lung adenocarcinoma
Motonobu Saito et al.
CANCER SCIENCE (2016)
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer
Gerald S. Falchook et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Naiyer A. Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues
Kuniko Sunami et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
New and emerging targeted treatments in advanced non-small-cell lung cancer
Fred R. Hirsch et al.
LANCET (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell et al.
NATURE GENETICS (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
Yoshitaka Seki et al.
ONCOLOGIST (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
Justin F. Gainor et al.
CANCER DISCOVERY (2016)
Development of Lung Adenocarcinomas with Exclusive Dependence on Oncogene Fusions
Motonobu Saito et al.
CANCER RESEARCH (2015)
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene
Hsu Wu et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer
Chee-Seng Tan et al.
LANCET ONCOLOGY (2015)
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kimberly H. Kim et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors
Jianfeng Shen et al.
CANCER DISCOVERY (2015)
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking
Maria E. Arcila et al.
CLINICAL CANCER RESEARCH (2015)
Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations
T. Kinno et al.
ANNALS OF ONCOLOGY (2014)
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis
Motonobu Saito et al.
CARCINOGENESIS (2014)
Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Takashi Nakaoku et al.
CLINICAL CANCER RESEARCH (2014)
A Three-microRNA Signature Predicts Responses to Platinum-Based Doublet Chemotherapy in Patients with Lung Adenocarcinoma
Motonobu Saito et al.
CLINICAL CANCER RESEARCH (2014)
RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib
Sanjay Mukhopadhyay et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes
Saravana M. Dhanasekaran et al.
NATURE COMMUNICATIONS (2014)
CD74-NRG1 Fusions in Lung Adenocarcinoma
Lynnette Fernandez-Cuesta et al.
CANCER DISCOVERY (2014)
A Synthetic Lethality-Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1
Takahiro Oike et al.
CANCER RESEARCH (2013)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Targeted therapy for NSCLC with driver mutations
Gabriele Minuti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Targeted therapy for non-small-cell lung cancer: past, present and future
Patrick M. Forde et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Levi A. Garraway
JOURNAL OF CLINICAL ONCOLOGY (2013)
Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Justin F. Gainor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A Patient with Lung Adenocarcinoma and RET Fusion Treated with Vandetanib
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts
Ayako Suzuki et al.
PLOS ONE (2013)
Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
Alexander Drilon et al.
CANCER DISCOVERY (2013)
Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing
Marcin Imielinski et al.
CELL (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
The transcriptional landscape and mutational profile of lung adenocarcinoma
Jeong-Sun Seo et al.
GENOME RESEARCH (2012)
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC
Kathy Gately et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Doron Lipson et al.
NATURE MEDICINE (2012)
KIF5B-RET fusions in lung adenocarcinoma
Takashi Kohno et al.
NATURE MEDICINE (2012)
RET, ROS1 and ALK fusions in lung cancer
Kengo Takeuchi et al.
NATURE MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non-Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts
Motonobu Saito et al.
CLINICAL CANCER RESEARCH (2011)
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paul K. Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
SWI/SNF nucleosome remodellers and cancer
Boris G. Wilson et al.
NATURE REVIEWS CANCER (2011)
分享论文
